Highest-materiality recent filing
Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment
Authorized shares increased from 150M to 200M via charter amendment filed May 28, 2026.
NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.
Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed
FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).
Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%
Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.
Relmada Therapeutics amends exec employment pacts; salaries raised for CEO, COO, CFO, CAO
CEO salary increased to $827,176 (+5% from $787,787); other terms unchanged.
Relmada reports NDV-01 92% CR rate; FDA alignment for Phase 3; closes $100M financing
NDV-01 9-month data: 92% complete response (CR) at any time in NMIBC; 91% in BCG-unresponsive subgroup; no Grade 3 TRAEs.
Relmada prices $100M underwritten offering of common stock and pre-funded warrants at $2.20/share
Priced 40.1M shares of common stock at $2.20/share and pre-funded warrants for 5.3M shares at $2.199/warrant.
FDA supports single-arm registrational trial in refractory BCG-unresponsive NMIBC and randomized trial in intermediate-risk NMIBC.
Relmada Therapeutics furnishes updated corporate presentation; details unavailable
8-K filed September 17, 2025 includes updated corporate presentation as Exhibit 99.1.
Relmada regains Nasdaq minimum bid price compliance; stock remains listed on Capital Market
Received Nasdaq written notice on Sept 15, 2025, confirming compliance with $1.00 minimum bid price rule after 10 consecutive trading days.
Relmada adds NDV-01 and sepranolone; NDV-01 Phase 2 shows 91% CR rate, Phase 3 planned 1H 2026
Added two Phase 2 candidates: NDV-01 (NMIBC) and sepranolone (Prader-Willi Syndrome/compulsivity disorders).
Relmada Therapeutics CMO-Urology buys 55,000 shares in open market on Aug 29, 2025
Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of RLMD common stock on August 29, 2025.
Relmada reports Q2 net loss $9.9M; NDV-01 91% overall response rate in NMIBC
Q2 net loss $9.9M ($0.30/shr) vs $17.8M ($0.59) a year ago; R&D expense fell to $2.8M from $10.7M.
Relmada Therapeutics gets Nasdaq transfer to Capital Market and 180-day bid-price extension
Nasdaq approved transfer to Capital Market effective July 24, 2025.
Relmada terminates esmethadone license agreement with Inturrisi and Manfredi
On July 7, 2025, Relmada delivered termination notice for the esmethadone License Agreement with Drs. Inturrisi and Manfredi.
Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program
Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.
Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan
Annual meeting held May 23, 2025; 53.6% quorum attained.
Marcum dismissed as independent auditor on May 8, 2025, following CBIZ CPAs' Nov 1, 2024 acquisition of Marcum's attest business.
Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC
90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.
Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone
Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).
Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025
Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).
Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome
Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.
Relmada Therapeutics receives Nasdaq deficiency notice for bid price below $1; 180-day cure period
Received Nasdaq notice on Jan 21, 2025, for failing minimum bid price of $1.00 for 30 consecutive business days through Jan 17, 2025.
Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments
Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.
Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review
Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.
Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis
DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.
Relmada shareholders reject equity plan increase and say-on-pay at annual meeting
Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.
Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024
Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).
Relmada Therapeutics CMO Cedric O'Gorman departs; separation agreement includes $414,500 payment
Dr. Cedric O'Gorman's service as Chief Medical Officer ended January 3, 2024, by mutual agreement.
Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned
REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.
Relmada Therapeutics CMO Cedric O'Gorman departs effective Jan 3, 2024
Dr. Cedric O'Gorman concluded his role as Chief Medical Officer on January 3, 2024, by mutual agreement.
Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track
Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.
Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024
Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).
Relmada Therapeutics updates corporate presentation on CNS pipeline
Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.
Relmada Therapeutics updates corporate presentation on October 4, 2023
Filed updated corporate presentation under Item 8.01; no financial or pipeline data disclosed.
Relmada reports Phase 3 open-label data for REL-1017 in MDD: rapid, sustained symptom improvement
In 204 de novo patients, mean MADRS total score improved 11.3 points at Day 7 and 22.5 points at Month 12.
Board member Eric Schmidt resigns; cites compliance for new sell-side analyst role
Eric Schmidt resigned from the Board effective September 5, 2023, with no disagreement with the company or management.
Relmada Therapeutics updates corporate presentation; no material new information disclosed
Company filed updated corporate presentation as Exhibit 99.1 on August 10, 2023.
Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024
Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.
Relmada Therapeutics stockholders approve plan amendment and elect directors
Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 2,500,000 to 7,900,000.
Relmada provides Phase 3 update for REL-1017 in MDD; cash $132.4M
Cash and equivalents $132.4M as of 3/31/23; ~30.1M common shares outstanding (45.6M as-converted).
Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update
Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.
Relmada Therapeutics updates corporate presentation, no financial data disclosed
Filed 8-K on April 19, 2023, to announce an updated corporate presentation.
Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.
Relmada confirms no cash or securities held at Silicon Valley Bank
Company discloses under Regulation FD that it holds no deposits or securities at SVB.
Relmada Therapeutics appoints Fabiana Fedeli to board of directors
Board expanded from 5 to 6 members; Fedeli appointed Class I director effective Jan 12, 2023.
Relmada Therapeutics appoints Cedric O'Gorman MD as Chief Medical Officer
Dr. O'Gorman appointed CMO effective January 9, 2023, leading medical, clinical, and regulatory for REL-1017 MDD program.
Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.
Relmada extends key man provisions in esmethadone license to Dec 31, 2027
Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.
RELIANCE I did not achieve statistical significance on MADRS at Day 28: REL-1017 -15.1 vs placebo -12.9 (2.2-point difference).
Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).
On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.
On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.
On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately.
increased the number of directors constituting the whole board from five to six and appointed Fabiana Fedeli as a Class I director of the Company
Max materiality 0.90 · Median 0.60 · Most common event other_material